SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

NEONC TECHNOLOGIES HOLDINGS, INC.
Date: May 2, 2025 · CIK: 0001979414 · Accession: 0000000000-25-004704

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286808

Date
May 2, 2025
Author
Division of
Form
UPLOAD
Company
NEONC TECHNOLOGIES HOLDINGS, INC.

Letter

Re: NeOnc Technologies Holdings, Inc. Registration Statement on Form S-1 Filed April 29, 2025 File No. 333-286808 Dear Thomas Chen:

May 2, 2025

Thomas Chen Chief Executive Officer NeOnc Technologies Holdings, Inc. 23975 Park Sorrento, Suite 205 Calabasas, CA 91302

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Thomas J. Poletti, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 2, 2025

Thomas Chen
Chief Executive Officer
NeOnc Technologies Holdings, Inc.
23975 Park Sorrento, Suite 205
Calabasas, CA 91302

 Re: NeOnc Technologies Holdings, Inc.
 Registration Statement on Form S-1
 Filed April 29, 2025
 File No. 333-286808
Dear Thomas Chen:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Alan Campbell at 202-551-4224 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Thomas J. Poletti, Esq.
</TEXT>
</DOCUMENT>